{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:34:39Z","timestamp":1792103679379,"version":"4.4.0"},"reference-count":105,"publisher":"Scientific Scholar","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>ANCA associated vasculitides are multi-system autoimmune diseases which are increasing in prevalence. In this review we will discuss the clinical manifestations and review the management options. We highlight the various trials of induction and maintenance therapy and discuss the areas of unmet need. These include understanding which patients are at highest risk of relapse, clinical adaptation of improved biomarkers of disease activity and tools to discuss long term prognosis<\/jats:p>","DOI":"10.4103\/ijn.ijn_346_23","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T14:00:21Z","timestamp":1702044021000},"source":"Crossref","is-referenced-by-count":3,"title":["ANCA-Associated Vasculitis: Practical Issues in Management"],"prefix":"10.25259","author":[{"given":"Tayeba","family":"Roper","sequence":"first","affiliation":[{"name":"UCL Department of Renal Medicine, Royal Free Hospital, London NW3 2PF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan David","family":"Salama","sequence":"additional","affiliation":[{"name":"UCL Department of Renal Medicine, Royal Free Hospital, London NW3 2PF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"key":"R1-20231211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international chapel hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R2-20231211","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s10067-015-3086-8","article-title":"A historical study of American patients with anti-neutrophil cytoplasmic antibody negative pauci-immune glomerulonephritis","volume":"35","author":"Shah","year":"2016","journal-title":"Clin Rheumatol"},{"key":"R3-20231211","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/annrheumdis-2012-201750","article-title":"Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis:A cluster analysis","volume":"72","author":"Mahr","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R4-20231211","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/bmj.2.5091.265","article-title":"Giant-cell granuloma of thfe respiratory tract (wegener's granulomatosis)","volume":"2","author":"Walton","year":"1958","journal-title":"BMJ"},{"key":"R5-20231211","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1093\/rheumatology\/ker112","article-title":"Overall survival, renal survival and relapse in patients with microscopic polyangiitis:A systematic review of current evidence","volume":"50","author":"Corral-Gudino","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"R6-20231211","first-page":"284","article-title":"Systemic vasculitis in the 1980s-Is there an increasing incidence of Wegener's granulomatosis and microscopic polyarteritis?","volume":"24","author":"Andrews","year":"1990","journal-title":"J R Coll Physicians Lond"},{"issue":"Suppl 3","key":"R7-20231211","doi-asserted-by":"crossref","first-page":"iii42","DOI":"10.1093\/rheumatology\/keaa089","article-title":"An update on the epidemiology of ANCA-associated vasculitis","volume":"59","author":"Mohammad","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R8-20231211","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/ard.60.2.170","article-title":"Geoepidemiology of systemic vasculitis:Comparison of the incidence in two regions of Europe","volume":"60","author":"Watts","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"R9-20231211","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1093\/rheumatology\/kex293","article-title":"Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"56","author":"Pearce","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R10-20231211","first-page":"1916","volume":"50","author":"Fujimoto","year":"2011","journal-title":"Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U. K. Rheumatology (Oxford)"},{"key":"R11-20231211","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1445-5994.2006.01297.x","article-title":"Wegener's granulomatosis in New Zealand:Evidence for a latitude-dependent incidence gradient","volume":"37","author":"O'Donnell","year":"2007","journal-title":"Intern Med J"},{"key":"R12-20231211","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/rheumatology\/kew232","article-title":"Incidence of ANCA-associated vasculitis in a UK mixed ethnicity population","volume":"55","author":"Pearce","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 1","key":"R13-20231211","doi-asserted-by":"crossref","first-page":"i14","DOI":"10.1093\/ndt\/gfv022","article-title":"Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"30","author":"Watts","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"R14-20231211","doi-asserted-by":"crossref","first-page":"13080","DOI":"10.1038\/s41598-021-92629-7","article-title":"A cohort study to investigate sex-specific differences in ANCA-associated glomerulonephritis outcomes","volume":"11","author":"Scott","year":"2021","journal-title":"Sci Rep"},{"key":"R15-20231211","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/1529-0131(200002)43:2<414::AID-ANR23>3.0.CO;2-0","article-title":"Epidemiology of systemic vasculitis:A ten-year study in the United Kingdom","volume":"43","author":"Watts","year":"2000","journal-title":"Arthritis Rheum"},{"key":"R16-20231211","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1172\/JCI0215918","article-title":"Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice","volume":"110","author":"Xiao","year":"2002","journal-title":"J Clin Invest"},{"key":"R17-20231211","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1182\/blood-2005-03-0921","article-title":"Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo","volume":"106","author":"Little","year":"2005","journal-title":"Blood"},{"key":"R18-20231211","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1046\/j.1523-1755.2001.00019.x","article-title":"Colocalization of ANCA-antigens and fibrinoid necrosis in ANCA-associated vasculitis","volume":"60","author":"Bajema","year":"2001","journal-title":"Kidney Int"},{"key":"R19-20231211","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/ard.60.12.1156a","article-title":"Epidemiology of vasculitis in Europe","volume":"60","author":"Watts","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"R20-20231211","doi-asserted-by":"crossref","first-page":"102660","DOI":"10.1016\/j.autrev.2020.102660","article-title":"Environmental risk factors associated with ANCA associated vasculitis:A systematic mapping review","volume":"19","author":"Scott","year":"2020","journal-title":"Autoimmun Rev"},{"key":"R21-20231211","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/art.24790","article-title":"Antineutrophil cytoplasmic antibody-associated vasculitides:Could geographic patterns be explained by ambient ultraviolet radiation?","volume":"61","author":"Gatenby","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R22-20231211","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.autrev.2013.06.016","article-title":"The association between silica exposure and development of ANCA-associated vasculitis:Systematic review and meta-analysis","volume":"12","author":"Gomez-Puerta","year":"2013","journal-title":"Autoimmun Rev"},{"key":"R23-20231211","doi-asserted-by":"crossref","first-page":"e0177482","DOI":"10.1371\/journal.pone.0177482","article-title":"The influence of the Great East Japan earthquake on microscopic polyangiitis:A retrospective observational study","volume":"12","author":"Takeuchi","year":"2017","journal-title":"PLoS One"},{"key":"R24-20231211","doi-asserted-by":"crossref","first-page":"12","DOI":"10.7326\/0003-4819-120-1-199401010-00003","article-title":"Association of chronic nasal carriage of staphylococcus aureus and higher relapse rates in wegener granulomatosis","volume":"120","author":"Stegeman","year":"1994","journal-title":"Ann Intern Me"},{"key":"R25-20231211","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.3390\/ijms24031822","article-title":"Using a network-based analysis approach to investigate the involvement of S. aureus in the pathogenesis of granulomatosis with polyangiitis","volume":"24","author":"Rowland","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R26-20231211","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2215\/CJN.03550807","article-title":"Hypotheses on the etiology of antineutrophil cytoplasmic autoantibody associated vasculitis:The cause is hidden, but the result is known","volume":"3","author":"de Lind van Wijngaarden","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R27-20231211","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/0140-6736(93)91761-A","article-title":"Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy","volume":"11","author":"Dolman","year":"1993","journal-title":"Lancet"},{"key":"R28-20231211","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/BOR.0000000000000014","article-title":"Trojan horses:Drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis","volume":"26","author":"Pendergraft","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"R29-20231211","doi-asserted-by":"crossref","first-page":"e002500","DOI":"10.1136\/rmdopen-2022-002500","article-title":"Immune checkpoint inhibitors as potential triggers for ANCA vasculitis","volume":"8","author":"Aqeel","year":"2022","journal-title":"RMD Open"},{"key":"R30-20231211","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors-a systematic review","volume":"37","author":"Daxini","year":"2018","journal-title":"Clin Rheumatol"},{"key":"R31-20231211","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/ckj\/sfab285","article-title":"De novo and relapsing necrotizing vasculitis after COVID-19 vaccination","volume":"15","author":"Fillon","year":"2022","journal-title":"Clin Kidney J"},{"key":"R32-20231211","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2174\/1573397113666170517155443","article-title":"Vasculitis following influenza vaccination:A review of the literature","volume":"13","author":"Watanabe","year":"2017","journal-title":"Curr Rheumatol Rev"},{"key":"R33-20231211","doi-asserted-by":"crossref","first-page":"rkad027","DOI":"10.1093\/rap\/rkad027","article-title":"Cocaine-induced granulomatosis with polyangiitis-an under-recognized condition","volume":"7","author":"Gill","year":"2023","journal-title":"Rheumatol Adv Pract"},{"key":"R34-20231211","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJMoa1108735","article-title":"Genetically distinct subsets within ANCA-associated vasculitis","volume":"367","author":"Lyons","year":"2012","journal-title":"N Engl J Med"},{"key":"R35-20231211","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/art.40034","article-title":"Identification of functional and expression polymorphisms associated with risk for antineutrophil cytoplasmic autoantibody-associated vasculitis","volume":"69","author":"Merkel","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R36-20231211","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3390\/jcm8020266","article-title":"Genetic variants in antineutrophil cytoplasmic antibody-associated vasculitis:A bayesian approach and systematic review","volume":"8","author":"Lee","year":"2019","journal-title":"J Clin Med"},{"key":"R37-20231211","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/annrheumdis-2021-221795","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis","volume":"81","author":"Robson","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R38-20231211","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/annrheumdis-2021-221796","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis","volume":"81","author":"Suppiah","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R39-20231211","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1183\/09031936.00110109","article-title":"Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis","volume":"36","author":"Tzelepis","year":"2010","journal-title":"Eur Respir J"},{"key":"R40-20231211","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1186\/ar4550","article-title":"Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study","volume":"16","author":"Sada","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"R41-20231211","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1056\/NEJM199711203372106","article-title":"Small vessel vasculitis","volume":"337","author":"Jennette","year":"1997","journal-title":"N Engl J Med"},{"key":"R42-20231211","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s00296-021-04966-5","article-title":"Classification of ANCA-associated vasculitis:Differences based on ANCA specificity and clinicopathologic phenotype","volume":"41","author":"Dominguez-Quintana","year":"2021","journal-title":"Rheumatol Int"},{"key":"R43-20231211","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s002810100074","article-title":"Imnmnopathological aspects of systemic vasculitis","volume":"23","author":"Bajema","year":"2001","journal-title":"Springer Semin Irnmunopathol"},{"key":"R44-20231211","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2010050477","article-title":"Histopathologic classification of ANCA-associated glomerulonephritis","volume":"21","author":"Berden","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R45-20231211","first-page":"671","article-title":"Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis","volume":"87","author":"Luqmani","year":"1994","journal-title":"QJM"},{"key":"R46-20231211","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/art.1780400222","article-title":"Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides","volume":"40","author":"Exley","year":"1997","journal-title":"Arthritis Rheum"},{"key":"R47-20231211","first-page":"789","article-title":"The dimensions of health outcomes:The health assessment questionnaire, disability and pain scales","volume":"9","author":"Fries","year":"1982","journal-title":"J Rheumatol"},{"key":"R48-20231211","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"R49-20231211","doi-asserted-by":"crossref","first-page":"1759720X20912646","DOI":"10.1177\/1759720X20912646","article-title":"Reactivation of hepatitis B virus infection in rheumatic diseases:Risk and management considerations","volume":"12","author":"Koutsianas","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R50-20231211","doi-asserted-by":"crossref","first-page":"e89777","DOI":"10.1371\/journal.pone.0089777","article-title":"Infective endocarditis with antineutrophil cytoplasmic antibody:Report of 13 cases and literature review","volume":"9","author":"Ying","year":"2014","journal-title":"PLoS One"},{"key":"R51-20231211","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000167998","article-title":"Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis","volume":"9","author":"Bolton","year":"1989","journal-title":"Am J Nephrol"},{"key":"R52-20231211","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R53-20231211","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12882-019-1226-0","article-title":"Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis:A multi-center retrospective cohort study","volume":"20","author":"Chanouzas","year":"2019","journal-title":"BMC Nephrol"},{"key":"R54-20231211","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"2010","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"R55-20231211","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1136\/annrheumdis-2019-216863","article-title":"Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis","volume":"79","author":"Smith","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R56-20231211","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"R57-20231211","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/jama.2021.6615","article-title":"Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis:A randomized clinical trial","volume":"325","author":"Furuta","year":"2021","journal-title":"JAMA"},{"key":"R58-20231211","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/acr2.11185","article-title":"Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis","volume":"2","author":"Merkel","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"R59-20231211","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"R60-20231211","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"R61-20231211","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0192-0561(79)90038-9","article-title":"The immunopharmacology of cyclophosphamide","volume":"1","author":"Shand","year":"1979","journal-title":"Int J Immunopharmacol"},{"key":"R62-20231211","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJM197104292841703","article-title":"Cyclophosphamide therapy in wegener's Granulomatosis","volume":"284","author":"Novack","year":"1971","journal-title":"N Engl J Med"},{"key":"R63-20231211","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophoshamide veresus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"De Groot","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R64-20231211","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2215\/CJN.11801018","article-title":"Mycophenolate mofetil versus cyclophosphamide for the induction of remission in nonlife-threatening relapses of antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"14","author":"Stassen","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"R65-20231211","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"EUVAS (European Vasculitis Study Group). Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis:A randomized trial","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Intern Me"},{"key":"R66-20231211","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis:Long-term follow-up","volume":"71","author":"Harper","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R67-20231211","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/art.25061","article-title":"Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases:A data-driven review","volume":"62","author":"Monach","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R68-20231211","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"R69-20231211","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1093\/ndt\/gfr127","article-title":"Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis","volume":"26","author":"Mansfield","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"R70-20231211","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/ndt\/gfx378","article-title":"Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"34","author":"McAdoo","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"R71-20231211","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/ki.1991.272","article-title":"Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies","volume":"40","author":"Pusey","year":"1991","journal-title":"Kidney Int"},{"key":"R72-20231211","doi-asserted-by":"crossref","first-page":"e064604","DOI":"10.1136\/bmj-2021-064604","article-title":"The effects of plasma exchange in patients with ANCA-associated vasculitis:An updated systematic review and meta-analysis","volume":"376","author":"Walsh","year":"2022","journal-title":"BMJ"},{"key":"R73-20231211","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1681\/ASN.2021060771","article-title":"Kidney histopathology can predict kidney function in ANCA-associated vasculitides with acute kidney injury treated with plasma exchanges","volume":"33","author":"Nezam","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"R74-20231211","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"NEJM"},{"key":"R75-20231211","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N Engl J Med"},{"key":"R76-20231211","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody\u2013associated vasculitis. A randomized controlled trial","volume":"304","author":"Walsh","year":"2010","journal-title":"JAMA"},{"key":"R77-20231211","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"R78-20231211","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard-2022-223559","article-title":"Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease:An international randomised controlled trial","volume":"82","author":"Smith","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R79-20231211","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/M19-3827","article-title":"Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis:A randomized trial","volume":"173","author":"Charles","year":"2020","journal-title":"Ann Intern Med"},{"key":"R80-20231211","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.3899\/jrheum.181438","article-title":"Malignancies in patients with antineutrophil cytoplasmic antibody-associated vasculitis:A population-based cohort study","volume":"47","author":"Heijl","year":"2020","journal-title":"J Rheumatol"},{"key":"R81-20231211","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.114.009990","article-title":"Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke:A population-based cohort study","volume":"130","author":"Dregan","year":"2014","journal-title":"Circulation"},{"key":"R82-20231211","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.33361","article-title":"Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Walsh","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R83-20231211","doi-asserted-by":"crossref","first-page":"rkab018","DOI":"10.1093\/rap\/rkab018","article-title":"Predicting relapse in anti-neutrophil cytoplasmic antibody-associated vasculitis:A Systematic review and meta-analysis","volume":"5","author":"King","year":"2021","journal-title":"Rheumatol Adv Pract"},{"key":"R84-20231211","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13075-017-1321-1","article-title":"Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse","volume":"19","author":"Morgan","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"R85-20231211","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ekir.2019.10.005","article-title":"Relapse in anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis","volume":"5","author":"Salama","year":"2020","journal-title":"Kidney Int Rep"},{"key":"R86-20231211","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1093\/ndt\/gfh487","article-title":"Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis","volume":"19","author":"Tam","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"R87-20231211","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1681\/ASN.2015050511","article-title":"Urinary soluble CD163 in active renal vasculitis","volume":"27","author":"O'Reilly","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"R88-20231211","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/rheumatology\/ken500","article-title":"Circulating neutrophil gelatinase-associated lipocalin:A useful biomarker for assessing disease activity of ANCA-associated vasculitis","volume":"48","author":"Chen","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"R89-20231211","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.ekir.2023.01.013","article-title":"Urinary T cells identify renal antineutrophil cytoplasmic antibody-associated vasculitis and predict prognosis:A proof of concept study","volume":"8","author":"Sonnemann","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"Suppl_1","key":"R90-20231211","article-title":"#4553 Real world data-driven identification of anca vasculitis relapse","volume":"38","author":"Scott","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"R91-20231211","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","article-title":"Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity","volume":"93","author":"Jayne","year":"2000","journal-title":"QJM"},{"key":"R92-20231211","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13075-022-02761-6","article-title":"Alemtuzumab for refractory primary systemic vasculitis-a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE)","volume":"24","author":"Gopaluni","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"R93-20231211","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1136\/annrheumdis-2013-204164","article-title":"An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's)","volume":"73","author":"Langford","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R94-20231211","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1681\/ASN.2014010046","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement","volume":"26","author":"Geetha","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"R95-20231211","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13063-023-07218-y","article-title":"A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS):Design of the study protocol","volume":"24","author":"McClure","year":"2023","journal-title":"Trials"},{"key":"R96-20231211","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1093\/rheumatology\/keab916","article-title":"Obinutuzumab compared with rituximab for treating ANCA-associated vasculitis","volume":"61","author":"Amudala","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R97-20231211","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/ndt\/gfac320","article-title":"Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis","volume":"38","author":"S\u00e1nchez \u00c1lamo","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"R98-20231211","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.2215\/CJN.01020113","article-title":"Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis","volume":"8","author":"de Joode","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"R99-20231211","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0272-6386(03)00025-8","article-title":"Outcome of ANCA-associated renal vasculitis:A 5-year retrospective study","volume":"41","author":"Booth","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"R100-20231211","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/ard.2007.071936","article-title":"Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis:A systematic review by the European League Against Rheumatism systemic vasculitis task force","volume":"67","author":"Mukhtyar","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R101-20231211","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R102-20231211","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.kint.2018.07.020","article-title":"Development and validation of a renal risk score in ANCA-associated glomerulonephritis","volume":"94","author":"Brix","year":"2018","journal-title":"Kidney Int"},{"key":"R103-20231211","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ekir.2023.01.039","article-title":"Renal recovery for patients with ANCA-associated vasculitis and low eGFR in the Advocate trial of AVACOPAN","volume":"8","author":"Cortazar","year":"2023","journal-title":"Kidney Int Rep"},{"key":"R104-20231211","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","article-title":"Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis:A randomised, non-inferiority trial","volume":"78","author":"Jones","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R105-20231211","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","article-title":"Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis","volume":"76","author":"Karras","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["Indian Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/ijn.ijn_346_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T19:47:29Z","timestamp":1712173649000},"score":1,"resource":{"primary":{"URL":"https:\/\/indianjnephrol.org\/?p=6784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,7]]},"references-count":105,"URL":"https:\/\/doi.org\/10.4103\/ijn.ijn_346_23","relation":{},"ISSN":["0971-4065","1998-3662"],"issn-type":[{"value":"0971-4065","type":"print"},{"value":"1998-3662","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,7]]}}}